natgillin/translations-raw huggingface dataset:
− Medicinal products that may reduce dexamethasone plasma concentration:
− zdravila, ki lahko zmanjšajo koncentracijo deksametazona v plazmi:
Neutropenia was the most frequently reported Grade 3 or 4 haematological adverse reaction in patients with relapsed/refractory multiple myeloma treated with the combination of dexamethasone with pomalidomide.
Nevtropenija je bila najpogosteje poročani hematološki neželeni učinek 3. ali 4. stopnje pri bolnikih z recidivnim ali proti zdravljenju odpornim multiplim mielomom, zdravljenih s kombinacijo deksametazona in pomalidomida.
Concomitant administration of erythropoietic medicinal products may also increase thrombotic risk in these patients.
Trombotično tveganje pri teh bolnikih se lahko poveča tudi zaradi sočasne uporabe eritropoetičnih zdravil.
Use of corticosteroids requires appropriate monitoring in patients with ulcerative colitis (due to perforation risk), recent intestinal anastomoses, diverticulitis, recent myocardial infarction (risk of left ventricular free wall rupture), diabetes mellitus (or family history), renal insufficiency, hepatic impairment, osteoporosis and myasthenia gravis.
Med uporabo kortikosteroidov je treba ustrezno spremljati bolnike z ulceroznim kolitisom (zaradi tveganja za predrtje), nedavnimi anastomozami črevesja, divertikulitisom, nedavnim srčnim infarktom (tveganje za rupturo proste stene levega prekata), sladkorno boleznijo (ali družinsko anamnezo te bolezni), ledvično insuficienco, okvaro jeter, osteoporozo in miastenijo gravis.
Effects of other medicinal products on dexamethasone Dexamethasone is metabolized via cytochrome P450 3A4 (CYP3A4), and transported by the P-glycoprotein (P-gp, also known as MDR1).
Deksametazon se presnavlja s citokromom P450 3A4 (CYP3A4), prenaša pa s P-glikoproteinom (P-gp, znan tudi kot MDR1).
Common: Liver function tests abnormal, alanine aminotransferase increased.
Bolezni jeter, žolčnika in žolčevodov pogosti: nenormalni izvidi preiskav delovanja jeter, povišana vrednost alanin-aminotransferaze.
Neofordex is a high-dose glucocorticoid.
Zdravilo Neofordex je visokoodmerni glukokortikoid.
Neofordex is a medicine that contains the active substance dexamethasone.
Neofordex je zdravilo, ki vsebuje učinkovino deksametazon.
Treatment for active gastric or duodenal ulceration should be commenced prior to initiation of corticosteroids.
Pred začetkom uporabe kortikosteroidov je treba uvesti zdravljenje za aktivno razjedo želodca ali dvanajstnika.
• With non-steroidal anti-inflammatory drugs (NSAIDs), due to an increased risk of gastrointestinal ulceration.
• z nesteroidnimi protivnetnimi zdravili (NSAID), saj se poveča tveganje za predrtje prebavil;
Other medicines and Neofordex Tell your doctor or pharmacist if you are taking, have recently taken or might take any other medicines.
Obvestite zdravnika ali farmacevta, če jemljete, ste pred kratkim jemali ali pa boste morda začeli jemati katero koli drugo zdravilo.
When Neofordex is given in combination with other medicinal products, refer to their Summaries of Product Characteristics for additional contraindications.
Če se bo zdravilo Neofordex uporabljalo v kombinaciji z drugimi zdravili, glejte njihove povzetke glavnih značilnosti zdravila za dodatne kontraindikacije.
Immunocompromised patients who have not previously had chickenpox or measles are particularly at risk.
Predvsem so v nevarnosti bolniki z oslabljenim imunskim sistemom, ki še niso imeli noric ali ošpic.
Neutropenia occurred in 45.3% of relapsed and refractory multiple myeloma patients who received low dose dexamethasone plus pomalidomide (Pom + LD-Dex), and in 19.5% of patients who received high dose dexamethasone (HD-Dex).
Nevtropenija se je pojavila pri 45,3 % bolnikov z recidivnim ali proti zdravljenju odpornim multiplim mielomom, ki so prejemali deksametazon v majhnem odmerku plus pomalidomid (Pom + LD-dex), ter pri 19,5 % bolnikov, ki so prejemali velik odmerek deksametazona (HD-dex).
The combination of lenalidomide, thalidomide or pomalidomide with dexamethasone is associated with an increased risk of deep vein thrombosis and pulmonary embolism in patients with multiple myeloma (see section 4.5).
Kombinacija lenalidomida, talidomida ali pomalidomida in deksametazona je pri bolnikih z multiplim mielomom povezana s povečanim tveganjem za globoko vensko trombozo in pljučno embolijo (glejte poglavje 4.5).
Do not take Neofordex
Ne jemljite zdravila Neofordex
10 x 1 tablets in OPA/Aluminium /PVC-Aluminium perforated unit dose blister.
10 x 1 tableta v perforiranem pretisnem omotu za enkratni odmerek iz OPA/aluminija/PVC-aluminija.
Patients must avoid contact with subjects with chickenpox or measles.
Zato se morajo bolniki izogibati stiku z osebami, ki imajo norice ali ošpice.
Other cytochrome P450 isoenzymes may also play a role in dexamethasone biotransformation.
Pri biotransformaciji deksametazona lahko sodelujejo tudi drugi izoencimi citokroma P450.
How to take Neofordex 4.
Kako jemati zdravilo Neofordex 4.
A similar incidence of high-grade neutropenia was reported in newly diagnosed patients treated with the combination of lenalidomide and dexamethasone.
O podobni incidenci nevtropenije visoke stopnje so poročali tudi pri bolnikih z na novo diagnosticirano boleznijo, ki so prejemali kombinacijo lenalidomida in deksametazona.
• Docetaxel and cyclophosphamide, due to reduction of their plasma levels by induction of CYP3A and P-gp.
• docetaksel in ciklofosfamid, saj se zaradi indukcije CYP3A in P-gp zmanjšajo njune koncentracije v plazmi;
Glucocorticoids have only weak acute toxicity.
Akutna toksičnost glukokortikoidov je majhna.
During treatment, a diet low in simple sugars and high in protein should be followed due to the hyperglycaemic effect of corticosteroids and their stimulation of protein catabolism with a negative nitrogen balance.
Kortikosteroidi delujejo hiperglikemično in spodbujajo razgradnjo beljakovin, kar povzroči negativno ravnovesje dušika, zato je med zdravljenjem treba uživati hrano z nizko vsebnostjo enostavnih sladkorjev in z visoko vsebnostjo beljakovin.
Neofordex will be given with other medicines for multiple myeloma.
Zdravilo Neofordex se uporablja skupaj z drugimi zdravili za multipli mielom.
In combination with thalidomide or its analogues the most serious adverse reactions were venous thromboembolic events, predominantly deep vein thrombosis and pulmonary embolism, and myelosuppression, particularly neutropenia and thrombocytopenia (see section 4.4).
Najresnejši neželeni učinki pri zdravljenju v kombinaciji s talidomidom ali njegovimi analogi so bili venski trombembolični dogodki, med katerimi sta prevladovali globoka venska tromboza in pljučna embolija, ter mielosupresija, zlasti nevtropenija in trombocitopenija (glejte poglavje 4.4).
Uncommon: Urticaria;
− odpoved ledvic;
In one study, 10.7% of patients treated with thalidomide and dexamethasone experienced grade 3/4 neuropathic reactions, compared to 0.9% of patients treated with dexamethasone alone.
stopnje pri 10,7 % bolnikov, zdravljenih s talidomidom in deksametazonom, v primerjavi z 0,9 % bolnikov, ki so jih zdravili samo z deksametazonom.
Each tablet contains dexamethasone acetate equivalent to 40 mg dexamethasone.
Ena tableta vsebuje deksametazonacetat v količini, ki ustreza 40 mg deksametazona.
Neutropenia was Grade 3 or 4 in 41.7% of patients who received Pom + LD-Dex, compared with 14.8% who received HD-Dex.
Nevtropenija je bila 3. ali 4. stopnje pri 41,7 % bolnikov, ki so prejemali Pom + LD-dex, in pri 14,8 % bolnikov, ki so prejemali HD-dex.
• Ivermectin, due to a reduction of ivermectin plasma levels.
• ivermektin, saj se zmanjša koncentracija ivermektina v plazmi.
Low-grade peripheral neuropathic reactions, predominantly grade 1 paraesthesia, may be observed with dexamethasone alone in up to 34% of newly diagnosed multiple myeloma patients.
Pri uporabi samega deksametazona se lahko pri največ 34 % bolnikov z na novo diagnosticiranim multiplim mielomom pojavijo periferne nevropatije nizke stopnje, predvsem parestezija 1. stopnje.
(purpura);
− koprivnica;
Common: Venous thromboembolic reactions, predominantly deep vein thrombosis and pulmonary embolism, hypertension, hypotension, flushing, blood pressure increased, diastolic blood pressure decreased;
Žilne bolezni pogosti: venski trombembolični neželeni učinki, zlasti globoka venska tromboza in pljučna embolija, hipertenzija, hipotenzija, zardevanje, zvišan krvni tlak, znižan diastolični krvni tlak; neznana pogostnost: purpura, podplutbe.
Thrombocytopenia occurred in 27.0% of relapsed and refractory multiple myeloma patients who received Pom + LD-Dex, and 26.8% of patients who received HD-Dex.
Trombocitopenija se je pojavila pri 27,0 % bolnikov z recidivnim ali proti zdravljenju odpornim multiplim mielomom, ki so prejemali Pom + LD-dex, in pri 26,8 % bolnikov, ki so prejemali HD-dex.
A similar incidence of high-grade thrombocytopenia was reported in newly diagnosed patients treated with the combination of lenalidomide and dexamethasone.
O podobni incidenci trombocitopenije visoke stopnje so poročali tudi pri bolnikih z na novo diagnosticirano boleznijo, ki so prejemali kombinacijo lenalidomida in deksametazona.
Common: may affect up to 1 in 10 people
Pogosti: pojavijo se lahko pri največ 1 od 10 bolnikov:
Hyperglycaemia, insomnia, muscle pain and weakness, asthenia, fatigue, oedema and weight increase occur very commonly.
Zelo pogosto se pojavijo hiperglikemija, nespečnost, bolečine v mišicah in šibkost mišic, astenija, utrujenost, edem in povečanje telesne mase.
− Reduction in the number of red or white blood cells and/or platelets, or increased number of white blood cells, decreased levels of potassium or of albumin (a protein) in the blood, increased levels of uric acid in the blood, changes in liver function tests;
− zmanjšanje števila rdečih in belih krvnih celic in/ali trombocitov ali povečanje števila belih krvnih celic,
Children do not develop multiple myeloma.
Otroci in mladostniki Multipli mielom se ne pojavlja pri otrocih.
− Rash, itching, reddened skin;
− izpuščaj, srbenje, pordela koža;
Thrombocytopenia was Grade 3 or 4 in 20.7% of patients who received Pom + LD-Dex and in 24.2% who received HD-Dex.
Trombocitopenija je bila 3. ali 4. stopnje pri 20,7 % bolnikov, ki so prejemali Pom + LD-dex, in pri 24,2 % bolnikov, ki so prejemali HD-dex.
In addition, convulsions have been reported with concurrent use of dexamethasone and ciclosporin.
Poleg tega so pri sočasni uporabi deksametazona in ciklosporina poročali o konvulzijah.
A complete blood cell count, including white blood cell count with differential count, platelet count, haemoglobin, and haematocrit should be performed at baseline, every week for the first 8 weeks of dexamethasone/lenalidomide treatment and monthly thereafter to monitor for cytopenias.
Pojav morebitnih citopenij je treba spremljati tako, da se ob začetku zdravljenja z deksametazonom/lenalidomidom in nato enkrat na teden prvih 8 tednov ter kasneje vsak mesec pregleda celotna krvna slika, vključno s številom belih krvnih celic skupaj z diferencialno krvno sliko, številom trombocitov, hemoglobinom in hematokritom.
− Vomiting, nausea, diarrhoea, indigestion, bloating, swollen and/or painful stomach;
− bruhanje, slabost, driska, prebavne motnje, napenjanje, napihnjen in/ali boleč želodec;
What Neofordex contains - The active substance is dexamethasone.
Kaj vsebuje zdravilo Neofordex - Učinkovina je deksametazon.
Neofordex administration should follow instructions for dexamethasone administration when described in the Summary of Product Characteristics of the associated treatment(s).
Pri uporabi zdravila Neofordex je treba upoštevati navodila za uporabo deksametazona, ki so opisana v povzetkih glavnih značilnosti zdravila za zdravila v kombinaciji.
Psychiatric disorders
Duševne motnje
• Praziquantel, due to the reduction of praziquantel plasma concentrations due to an increase of its hepatic metabolism by dexamethasone, with a risk of failure of treatment.
• prazikvantel, saj deksametazon poveča jetrno presnovo prazikvantela, zaradi česar se zmanjša njegova koncentracija v plazmi in se pojavi tveganje za neuspešno zdravljenje.
neofordex UNIQUE IDENTIFIER - 2D BARCODE
EDINSTVENA OZNAKA - DVODIMENZIONALNA ČRTNA KODA
You must read the package leaflets of all medicinal products to be taken in combination with Neofordex for information related to these medicines before starting treatment with Neofordex.
Pred začetkom jemanja zdravila Neofordex morate za informacije, povezane z zdravili, ki jih boste jemali v kombinaciji z zdravilom Neofordex, prebrati navodila za uporabo za vsa ta zdravila.
Prior to the use of Neofordex in combination with any other medicinal product, reference should be made to the Summary of Product Characteristics of that product.
Pred uporabo zdravila Neofordex v kombinaciji s katerim koli drugim zdravilom je treba prebrati povzetek glavnih značilnosti zdravila za izbrano zdravilo.
How to store Neofordex 6.
Shranjevanje zdravila Neofordex 6.
Common: Depression, anxiety, aggression, confusional state, irritability, nervousness, mood alteration, agitation, euphoric mood; Uncommon: Mood swings, hallucinations;
Duševne motnje zelo pogosti: nespečnost; pogosti: depresija, tesnoba, agresija, zmedenost, razdražljivost, živčnost, spremembe razpoloženja, agitacija, evforično razpoloženje; občasni: nihanja razpoloženja, halucinacije; neznana pogostnost: manija, psihoza, vedenjske motnje.
Grade 4 febrile neutropenia episodes were observed infrequently (0.6% in lenalidomide/dexamethasone-treated patients compared to 0.0% in placebo/dexamethasone treated patients).
Epizode febrilne nevtropenije 4. stopnje so opazili redko (0,6 % pri bolnikih, ki so prejemali lenalidomid/deksametazon, v primerjavi z 0,0 % pri bolnikih, ki so prejemali placebo/deksametazon).
• Ciclosporin, due to a reduction of ciclosporin bioavailability and plasma levels.
• ciklosporin, saj se zmanjšata biološka uporabnost in plazemska koncentracija ciklosporina.
Neofordex contains lactose.
Zdravilo Neofordex vsebuje laktozo.
In patients with multiple myeloma, the combination of dexamethasone with thalidomide and its analogues is associated with an increased risk of venous thromboembolism (predominantly deep vein thrombosis and pulmonary embolism) and arterial thromboembolism (predominantly myocardial infarction and cerebrovascular event) (see sections 4.5 and 4.8).
Kombinacija deksametazona in talidomida ter njegovih analogov lahko pri bolnikih z multiplim mielomom poveča tveganje za vensko trombembolijo (predvsem za globoko vensko trombozo in pljučno embolijo) ter arterijsko trombembolijo (predvsem za srčni infarkt in cerebrovaskularne dogodke) (glejte poglavji 4.5 in
− Pain, fever, chills, fainting, vertigo, exhaustion, drowsiness, impaired sense of balance.
− bolečine, zvišana telesna temperatura, mrzlica, omedlevica, vrtoglavica, izčrpanost, zaspanost, motnje ravnotežja;
Grade 4 febrile neutropenia episodes were observed infrequently (0.6% in lenalidomide/dexamethasone-treated patients compared to 0.0% in placebo/dexamethasone treated patients; see section 4.8).
Epizode febrilne nevtropenije 4. stopnje so opazili redko (0,6 % pri bolnikih, ki so prejemali lenalidomid/deksametazon, in 0,0 % pri bolnikih, ki so prejemali placebo/deksametazon; glejte poglavje 4.8).
Thrombocytopenia was also reported very commonly by patients with relapsed/refractory multiple myeloma treated with the combination of dexamethasone with pomalidomide.
O trombocitopeniji so zelo pogosto poročali tudi bolniki z recidivnim ali proti zdravljenju odpornim multiplim mielomom, zdravljeni s kombinacijo deksametazona in pomalidomida.
Depending on the duration of treatment, calcium metabolism may be impaired.
Med dolgotrajnejšim zdravljenjem se lahko zmanjša presnova kalcija.
Reference should be made to all the relevant Summary of Product Characteristics prior to the commencement of any combination treatment for additional information.
Pred uvedbo zdravljenja s katero koli kombinacijo je treba za več informacij prebrati vse zadevne povzetke glavnih značilnosti zdravil.
Dexamethasone is a type of hormone called a glucocorticoid, sometimes called a corticoid or corticosteroid, with various actions including effects on white blood cells, which form part of the immune system (the body's natural defences).
Deluje na različne načine, med drugim vpliva na bele krvne celice, ki so del imunskega sistema (naravne telesne obrambe).
You may experience serious side effects if you stop taking this medicine suddenly.
Nenadno prenehanje jemanja tega zdravila lahko povzroči resne neželene učinke.
Common: Pneumonia, herpes zoster, upper respiratory tract infection, lower respiratory tract infection, oral candidiasis, oral fungal infection, urinary tract infection, herpes simplex, candidal infection;
Infekcijske in parazitske bolezni pogosti: pljučnica, herpes zoster, okužba zgornjih dihal, okužba spodnjih dihal, ustna kandidoza, glivična okužba ust, okužba sečil, herpes simpleks, okužba s kandido; neznana pogostnost: okužba, sepsa.
Common: Weight decreased, weight increased.
Preiskave pogosti: zmanjšanje telesne mase, povečanje telesne mase.
Common: Peripheral neuropathy, dizziness, psychomotor hyperactivity, disturbance in attention, memory impairment, tremor, paraesthesia, headache, ageusia, dysgeusia, somnolence, lethargy, balance impaired, dysphonia;
Bolezni živčevja pogosti: periferna nevropatija, omotica, psihomotorna hiperaktivnost, motnje pozornosti, oslabljen spomin, tremor, parestezija, glavobol, agevzija, disgevzija, somnolenca, letargija, motnje ravnotežja, disfonija; občasni: cerebrovaskularni inzult, prehodni ishemični napad, amnezija, motnje koordinacije, ataksija, sinkopa; neznana pogostnost: konvulzije.
However, the immune response and hence the effect of the vaccination can be diminished by high glucocorticoid doses.
Vendar pa lahko veliki odmerki glukokortikoidov zmanjšajo imunski odziv in posledično učinek cepljenja.
• Midazolam, due a reduction in midazolam plasma levels by CYP3A4 induction.
• midazolam, saj se zaradi indukcije CYP3A4 zmanjša koncentracija midazolama v plazmi.
• Obligation to conduct post-authorisation measures N/A
• Obveznost za izvajanje ukrepov po pridobitvi dovoljenja za promet z zdravilom Navedba smiselno ni potrebna.
How to take Neofordex
Kako jemati zdravilo Neofordex
The combination of lenalidomide with dexamethasone in relapsed or refractory multiple myeloma patients is associated with a higher incidence of grade 3 and grade 4 thrombocytopenia (9.9% and 1.4%, respectively, in lenalidomide/dexamethasone-treated patients compared to 2.3% and 0.0% in placebo/dexamethasone-treated patients).
Kombinacija lenalidomida in deksametazona je pri bolnikih z recidivnim ali proti zdravljenju odpornim multiplim mielomom povezana s povečano incidenco trombocitopenije 3. in 4. stopnje (9,9 % oziroma 1,4 % pri bolnikih, ki so prejemali lenalidomid/deksametazon, v primerjavi z 2,3 % oziroma 0,0 % pri bolnikih, ki so prejemali placebo/deksametazon).
• Indinavir, due to a strong reduction of indinavir plasma levels by intestinal CYP3A4 induction.
• indinavir, saj se zaradi indukcije CYP3A4 v črevesju močno zmanjša koncentracija indinavirja v plazmi;
When Neofordex is given in combination with other medicinal products, the Summary of Product Characteristics of these other medicinal products must be consulted prior to initiation of treatment with Neofordex.
Uporaba v kombinaciji z enim ali več drugimi zdravili za multipli mielom Če se bo zdravilo Neofordex uporabljalo v kombinaciji z drugimi zdravili, je treba pred uvedbo zdravila Neofordex prebrati povzetek glavnih značilnosti zdravila za ta druga zdravila.
Neofordex contains lactose, a sugar.
Zdravilo Neofordex vsebuje laktozo (sladkor).
The combination of lenalidomide with dexamethasone in relapsed or refractory multiple myeloma patients is associated with a higher incidence of grade 4 neutropenia (5.1% in lenalidomide/dexamethasone-treated patients compared with 0.6% in placebo/dexamethasone-treated patients).
Kombinacija lenalidomida in deksametazona je pri bolnikih z recidivnim ali proti zdravljenju odpornim multiplim mielomom povezana s povečano incidenco nevtropenije 4. stopnje (5,1 % pri bolnikih, ki so prejemali lenalidomid/deksametazon, v primerjavi z 0,6 % pri bolnikih, ki so prejemali placebo/deksametazon).
The combination of dexamethasone with lenalidomide in multiple myeloma patients is associated with a higher incidence of grade 3 and grade 4 thrombocytopenia (9.9% and 1.4%, respectively, in lenalidomide/dexamethasone-treated patients compared to 2.3% and 0.0% in placebo/dexamethasone-treated patients) (see section 4.8).
Kombinacija deksametazona in lenalidomida je pri bolnikih z multiplim mielomom povezana s povečano incidenco trombocitopenije 3. in 4. stopnje (9,9 % oziroma 1,4 % pri bolnikih, ki so prejemali lenalidomid/deksametazon, v primerjavi z 2,3 % oziroma 0,0 % pri bolnikih, ki so prejemali placebo/deksametazon) (glejte poglavje 4.8).
• With rifampicin, due to reduction of dexamethasone plasma concentrations and efficacy by an increase of its hepatic metabolism.
• rifampicin, saj se zaradi povečane jetrne presnove deksametazona zmanjšata njegova koncentracija v plazmi in učinkovitost;
The combination of dexamethasone with lenalidomide in multiple myeloma patients is associated with a higher incidence of grade 4 neutropenia (5.1% in lenalidomide/dexamethasone-treated patients compared with 0.6% in placebo/dexamethasone-treated patients; see section 4.8).
Kombinacija deksametazona in lenalidomida je pri bolnikih z multiplim mielomom povezana s povečano incidenco nevtropenije 4. stopnje (5,1 % pri bolnikih, ki so prejemali lenalidomid/deksametazon, v primerjavi z 0,6 % pri bolnikih, ki so prejemali placebo/deksametazon; glejte poglavje 4.8).
• Rifabutin, due to reduced rifabutin plasma levels by induction of intestinal and hepatic CYP3A4.
• rifabutin, saj se zaradi indukcije CYP3A4 v črevesju in jetrih zmanjša koncentracija rifabutina v plazmi;
• Ephedrine, due to a reduction in dexamethasone plasma levels by increased metabolic clearance.
• efedrin, saj se zaradi povečanega presnovnega očistka zmanjšajo koncentracije deksametazona v plazmi;
What Neofordex looks like and contents of the pack Each tablet is white, oblong in shape, with a score line on one face.
Vsaka tableta je bela, podolgovata in ima na eni strani razdelilno zarezo.
How to store Neofordex
Shranjevanje zdravila Neofordex
Common: Atrial fibrillation, supraventricular extrasystoles, tachycardia, palpitations;
Srčne bolezni pogosti: atrijska fibrilacija, supraventrikularne ekstrasistole, tahikardija, palpitacije; občasni: srčna ishemija, bradikardija; neznana pogostnost: kongestivno srčno popuščanje.
• Aminogluthetimide, due to a reduction of the efficacy of dexamethasone through an increase of its hepatic metabolism.
• aminoglutetimid, saj se zaradi povečane jetrne presnove deksametazona zmanjša njegova učinkovitost;
You must avoid getting pregnant during treatment with Neofordex.
Med jemanjem zdravila Neofordex morate preprečiti zanositev.
Effects of dexamethasone on other medicinal products Dexamethasone is a moderate inducer of CYP3A4 and of P-gp.
Deksametazon je zmeren induktor CYP3A4 in P-gp.
Concomitant administration of erythropoietic medicinal products or previous history of deep vein thrombosis may also increase thrombotic risk in these patients.
Trombotično tveganje pri teh bolnikih se lahko poveča tudi zaradi sočasne uporabe eritropoetičnih zdravil ali anamneze globoke venske tromboze.
Very common: Muscular weakness, muscle cramps; Common: Myopathy, musculoskeletal pain, arthralgia, pain in extremity;
Bolezni mišično-skeletnega sistema in vezivnega tkiva zelo pogosti: mišična šibkost, mišični krči; pogosti: miopatija, mišično-skeletna bolečina, artralgija, bolečine v udih; neznana pogostnost: patološki zlom, osteonekroza, osteoporoza, pretrganje kite.
• Aprepitant and fosaprepitant, due to an increase of dexamethasone plasma concentrations by a reduction of its hepatic metabolism.
• aprepitant in fosaprepitant, saj se zaradi zmanjšane jetrne presnove deksametazona poveča njegova koncentracija v plazmi;